Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus

Histopathology

Volumn 63, Issue 5, 2013, Pages 630-639

  Kastelein, Florine ^a   Biermann, Katharina ^a   Steyerberg, Ewout W ^a   Verheij, Joanne ^b   Kalisvaart, Marit ^a   Looijenga, Leendert H J ^a   Stoop, Hans A ^a   Walter, Laurens ^a   Kuipers, Ernst J ^a   Spaander, Manon C W ^a   Bruno, Marco J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

methylacyl CoA racemase; Barrett's esophagus; Biomarker; Oesophageal adenocarcinoma; P504S

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR BIOPSY;

BARRETT'S ESOPHAGUS; BIOMARKER; OESOPHAGEAL ADENOCARCINOMA; P504S; Α-METHYLACYL-COA RACEMASE;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84885424396     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12216     Document Type: Article

References (19)

1. Falk GW. Barrett's esophagus. Gastroenterology 2002; 122; 1569-1591.
2. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010; 59; 1030-1036.
3. Sikkema M, deJonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2010; 8; 235-244.
4. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96(5 Pt 1); 1249-1256.
5. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129; 1825-1831.
6. Wang JS, Canto MI. Predicting neoplastic progression in Barrett's esophagus. Ann. Gastroenterol. Hepatol. 2010; 1; 1-10.
7. Kerkhof M, van Dekken H, Steyerberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50; 920-927.
8. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 2000; 95; 3383-3387.
9. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 2006; 30; 871-877.
10. Lisovsky M, Falkowski O, Bhuiya T. Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum. Pathol. 2006; 37; 1601-1606.
11. Scheil-Bertram S, Lorenz D, Ell C, Sheremet E, Fisseler-Eckhoff A. Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus. Mod. Pathol. 2008; 21; 961-967.
12. Shi XY, Bhagwandeen B, Leong AS. P16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl. Immunohistochem. Mol. Morphol. 2008; 16; 447-452.
13. Sonwalkar SA, Rotimi O, Scott N et al. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase). Histopathology 2010; 56; 900-907.
14. Strater J, Wiesmuller C, Perner S, Kuefer R, Moller P. Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia. Histopathology 2008; 52; 399-402.
15. Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 2002; 97; 1888-1895.
16. DiBaise JK, The LA. classification for esophagitis: a call for standardization. Am. J. Gastroenterol. 1999; 94; 3403-3404.
17. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett Practice Parameters Committee of the American College of G s esophagus: the Prague C & M criteria. Gastroenterology 2006; 131; 1392-1399.
18. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105; 40-50.
19. Ong CA, Lao-Sirieix P, Fitzgerald RC. Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J. Gastroenterol. 2010; 16; 5669-5681.